Sign in

CSBR on Nasdaq

Champions Oncology

Logo: https://www.championsoncology.com/, Non-free logo, via Wikipedia5

American technology company

Champions Oncology is an American technology company that develops mouse avatars. Called TumorGrafts, they are used to test a panel of chemotherapy regimens, targeted therapies and monoclonal antibodies to identify potential therapeutic options for cancer patients. The company was founded in 2007 by David Sidransky, M.D., a Johns Hopkins University oncologist.3 Its shares trade on Nasdaq under the symbol CSBR.1 Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 21, 2026.

Overview

$59.4MRevenue, fiscal 20266
-$1.2MNet income, fiscal 20266
2001Founded1

Compare with Invivyd, Inc., Protalix Biotherapeutics Inc or VIR Biotechnology, or pick any stock.

  • TickerCSBR on Nasdaq1
  • IndustryBiological Products, (No Diagnostic Substances)1
  • HeadquartersHackensack1
  • Websitechampionsoncology.com
  • Incorporated inDE7
  • Business address855 N. Wolfe Street, Suite 619, Baltimore, Md 212057
  • Filer categoryNon-accelerated filer, Smaller reporting company7
  • Legal formCorporation4
  • LEI549300O8WKLP8QEG5U474
  • StatusActive4
  • LEI statusLapsed (not renewed)4
  • Registered addressC/O Corporation Service Company, 19808 Wilmington, United States4

See how the biggest companies compare on our leaderboards

Champions Oncology is an American technology company that develops mouse avatars. Called TumorGrafts, they are used to test a panel of chemotherapy regimens, targeted therapies and monoclonal antibodies to identify potential therapeutic options for cancer patients. The company was founded in 2007 by David Sidransky, M.D., a Johns Hopkins University oncologist.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2026

-1.9%Operating margin6
-2.0%Net margin6
4.4%Revenue growth, 20266
-29.8%Return on equity6
-$5.0MFree cash flow6

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Pharmacology Services brought in 96% of the revenue Champions Oncology broke down this way in fiscal 2026.

  1. Pharmacology Services$57.1M696%up 18% from 2025
  2. Product and Service, Other$1.5M63%down 59% from 2025
  3. Translational Oncology Solutions (TOS) License Revenue$764.0K61%down 84% from 2025
Products and services by year
Products and services20252026
Pharmacology Services$48.6M$57.1M
Product and Service, Other$3.7M$1.5M
Translational Oncology Solutions (TOS) License Revenue$4.7M$764.0K

Where the money goes

Where each dollar of revenue went, fiscal 2026

  • Cost of revenue52¢$30.9M
  • Research and development15¢$9.1M
  • Other costs32¢$19.2M
  • Income tax0¢$246.0K

Out of $59.4M in revenue.6 The company lost money this year.

Financial statements

Revenue89101112136$59.4M in 2026+120% since 2019
0$20.0M$40.0M$60.0M2019: $27.1M$27.1M20192020: $32.1M$32.1M2020+19%2021: $41.0M$41.0M2021+28%2022: $49.1M$49.1M2022+20%2023: $53.9M$53.9M2023+10%2024: $50.2M$50.2M2024−7%2025: $56.9M$56.9M2025+14%2026: $59.4M$59.4M2026+4%
Operating income89101112136-$1.1M in 2026
-$10.0M-$5.0M0$5.0M2019: $270.0K$270.0K20192020: -$1.9M-$1.9M20202021: $366.0K$366.0K20212022: $607.0K$607.0K2022+66%2023: -$5.3M-$5.3M20232024: -$7.4M-$7.4M2024+40%2025: $4.6M$4.6M20252026: -$1.1M-$1.1M2026
Net income89101112136-$1.2M in 2026
-$10.0M-$5.0M0$5.0M2019: $128.0K$128.0K20192020: -$2.1M-$2.1M20202021: $362.0K$362.0K20212022: $548.0K$548.0K2022+51%2023: -$5.3M-$5.3M20232024: -$7.3M-$7.3M2024+36%2025: $4.7M$4.7M20252026: -$1.2M-$1.2M2026

Every line of the income statement as filed: the last 2 fiscal years, latest first.6

Period ending2026-04-302025-04-30
Oncology revenue$59.4M$56.9M
Cost of oncology revenue$30.9M$28.4M
Research and development$9.1M$6.8M
Sales and marketing$9.3M$7.5M
General and administrative$11.2M$9.3M
Loss on disposal of equipment$111.0K$293.0K
Total costs and operating expenses$60.6M$52.4M
Income (loss) from operations-$1.1M$4.6M
Other income, net$211.0K$73.0K
Income (loss) before income tax expense-$929.0K$4.6M
Provision (benefit) for income tax$246.0K-$75.0K
Net income (loss)-$1.2M$4.7M
basic (in dollars per share)-$0.08$0.34
diluted (in dollars per share)-$0.08$0.33
basic (in shares)13.8M shares13.7M shares
diluted (in shares)13.8M shares14.3M shares

Compare Champions Oncology with another company

Corporate structure

Champions Oncology sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Champions Oncology

  • Champions Oncology Hackensack, New Jersey, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Champions Oncology reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$16.4M6 Apr 30, 2026$16.1M6 Apr 30, 2025+2.2%
Accumulated depreciation$12.9M6 Apr 30, 2026$11.7M6 Apr 30, 2025+10.3%
Finance-lease assets$85.0K6 Apr 30, 2026$220.0K6 Apr 30, 2025−61.4%
Operating-lease assets (leased space)$3.7M6 Apr 30, 2026$5.1M6 Apr 30, 2025−27.2%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$335.0K6 Apr 30, 2026$335.0K6 Apr 30, 20250%

Properties, in its own words

The Company currently leases its office and laboratory facilities under non-cancelable operating leases. Rent expense for operating leases is recognized on a straight-line basis over the lease term from the lease commencement date through the scheduled expiration date. Rent expenses totaled $1.8 million for the years ended April 30, 2026 and 2025. The Company considers its facilities adequate for its current operational needs.

The Company leases the following facilities:

The rest of Item 2

•One University Plaza, Suite 307, Hackensack, New Jersey 07601, which, since November 2011, serves as the Company’s corporate headquarters. The lease expires in November 2026. The Company recognized $78,000 and $75,000 of rental costs relative to this lease for fiscal 2026 and 2025, respectively.

•1330 Piccard Drive, Suite 025, Rockville, MD 20850, which consists of laboratory and office space where the Company conducts operations related to its primary service offerings. The lease expires February 28, 2029. The Company recognized $1.7 million of rental costs relative to this lease for each of fiscal 2026 and 2025.

•VIA LEONE XIII, 14, Milan, Italy, which consists of laboratory and office space where the Company conducts operations related to its flow cytometry service offerings. The lease was set to expire October 31, 2028, however, the Company terminated the lease effective April 30, 2026. The Company recognized $50,000 of rental costs in Italy for each of fiscal 2026 and 2025.

Item 2 of the 10-K filed Jul 27, 2026.18

Leadership

Who has led Champions Oncology, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Joel Ackerman2010–2016
  2. Ronnie Morris2018–2023
  3. Robert Lawrence Brainin2026–now

Chair

  1. David Sidransky2009

President

  1. Douglas D. Burkett2008
  2. Ronnie Morris2010–2016
  3. Brady Davis2024

Chief financial officer

  1. Mark Schonau2009–2010
20052010201520202025
Board members and other officers (12)

Former names

  • CHAMPIONS BIOTECHNOLOGY, INC.Mar 19, 2007 to Mar 30, 20117
  • CHAMPIONS SPORTS INCSep 13, 1995 to Feb 16, 20077

Timeline

  1. Sep 10, 20268-K Results of operations37
  2. Jul 27, 20268-K Results of operations38
  3. Mar 30, 20268-K Executive or director change39
  4. Mar 12, 20268-K Results of operations40
  5. Jan 30, 2026New chief executive Robert Lawrence Brainin becomes CEO19
  6. Dec 15, 20258-K Results of operations41
  7. Oct 16, 20258-K Shareholder vote42
  8. Sep 15, 20258-K Results of operations43
  9. Jul 23, 20258-K Results of operations44
  10. Jul 21, 20258-K Financial statements and exhibits45
  11. Mar 11, 20258-K Results of operations46
  12. Dec 11, 20248-K Results of operations47
  13. Oct 15, 20248-K Shareholder vote48
  14. Mar 26, 2018New chief executive Ronnie Morris becomes CEO20
  15. Oct 29, 2010New chief executive Joel Ackerman becomes CEO21
  16. 2001Founded Founded1

Calendar

When it reported results

  1. Sep 10, 2026Reported quarterly or annual results37
  2. Jul 27, 2026Reported quarterly or annual results38
  3. Mar 12, 2026Reported quarterly or annual results40
  4. Dec 15, 2025Reported quarterly or annual results41
  5. Sep 15, 2025Reported quarterly or annual results43
  6. Jul 23, 2025Reported quarterly or annual results44
  7. Mar 11, 2025Reported quarterly or annual results46
  8. Dec 11, 2024Reported quarterly or annual results47

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

135 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 30 major events, 65 insider forms, 5 large holders, 15 other. The latest 20:

  1. Sep 11, 202610-Q EDGAR
  2. Sep 10, 20268-K EDGAR
  3. Aug 28, 2026DEFA14A EDGAR
  4. Aug 28, 2026DEF 14A EDGAR
  5. Jul 27, 202610-K EDGAR
  6. Jul 27, 20268-K EDGAR
  7. Mar 30, 20268-K EDGAR
  8. Mar 12, 202610-Q EDGAR
  9. Mar 12, 20268-K EDGAR
  10. Jan 30, 20264 EDGAR
  11. Jan 30, 20264 EDGAR
  12. Jan 16, 20263 EDGAR
  13. Dec 15, 202510-Q EDGAR
  14. Dec 15, 20258-K EDGAR
  15. Nov 7, 20254 EDGAR
  16. Nov 7, 20254 EDGAR
  17. Nov 7, 20254 EDGAR
  18. Nov 7, 20254 EDGAR
  19. Nov 7, 20254 EDGAR
  20. Nov 6, 20254 EDGAR

The 135 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

26 open-market trades by officers, directors and large owners since October 2021: 26 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jan 12, 2024Mendelson Daniel NewmanDirectorBuy1,000$6.50$6.5KForm 4
Jan 11, 2024Mendelson Daniel NewmanDirectorBuy2,000$6.27$12.5KForm 4
Jan 10, 2024Mendelson Daniel NewmanDirectorBuy2,944$6.31$18.6KForm 4
Jan 9, 2024Mendelson Daniel NewmanDirectorBuy3,000$6.25$18.8KForm 4
Jan 8, 2024Mendelson Daniel NewmanDirectorBuy1,000$6.15$6.2KForm 4
Jan 5, 2024Mendelson Daniel NewmanDirectorBuy2,000$6.09$12.2KForm 4
Jan 4, 2024Mendelson Daniel NewmanDirectorBuy3,000$6.12$18.4KForm 4
Jan 3, 2024Mendelson Daniel NewmanDirectorBuy500$5.83$2.9KForm 4
Dec 21, 2023Mendelson Daniel NewmanDirectorBuy2,500$4.92$12.3KForm 4
Dec 20, 2023Mendelson Daniel NewmanDirectorBuy2,100$4.82$10.1KForm 4
Dec 19, 2023Mendelson Daniel NewmanDirectorBuy5,000$4.75$23.8KForm 4
Oct 11, 2023Mendelson Daniel NewmanDirectorBuy5,000$6.40$32.0KForm 4
Oct 10, 2023Mendelson Daniel NewmanDirectorBuy1,100$6.41$7.1KForm 4
Oct 6, 2023Mendelson Daniel NewmanDirectorBuy1,530$6.48$9.9KForm 4
Oct 5, 2023Mendelson Daniel NewmanDirectorBuy2,000$6.47$12.9KForm 4
Oct 4, 2023Mendelson Daniel NewmanDirectorBuy5,000$6.40$32.0KForm 4
Oct 3, 2023Mendelson Daniel NewmanDirectorBuy2,500$6.30$15.8KForm 4
Sep 29, 2023Mendelson Daniel NewmanDirectorBuy4,000$6.16$24.6KForm 4
Sep 28, 2023Mendelson Daniel NewmanDirectorBuy5,000$6.22$31.1KForm 4
Sep 27, 2023Mendelson Daniel NewmanDirectorBuy1,500$5.95$8.9KForm 4

All 26 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2026Robert Brainin$346.2K$3.6M52
2026David Miller$315.0K$388.5K52
2026Ronnie Morris$233.3K52
2025Chief Executive Officer$400.0K$600.0K52
2025Chief Financial Officer$278.3K$310.8K52
2025President$177.1K52

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 27. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Battery Management Corp.2,421,673$14.9M4.1%No change
NEA Management Company, LLC1,713,720$10.6M0.7%No change
Vanguard Capital Management LLC301,353$1.9M0.0%+1,833
Tocqueville Asset Management L.P.295,658$1.8M0.0%−24,016
Morgan Stanley235,400$1.5M0.0%−6,900
Bank Of America Corp /de/214,058$1.3M0.0%+192,225
Renaissance Technologies LLC139,039$856.5K0.0%−6,500
BlackRock, Inc.129,848$799.9K0.0%+5,948
Mink Brook Asset Management LLC111,338$685.8K0.3%No change
Geode Capital Management, LLC76,300$470.1K0.0%−877
HighTower Advisors, LLC41,901$258.1K0.0%+6,743
Vanguard Fiduciary Trust Co33,239$204.8K0.0%+247
Northern Trust Corp27,910$171.9K0.0%−18,022
State Street Corp26,203$161.4K0.0%No change
Bank of New York Mellon Corp21,614$133.1K0.0%No change
Citadel Advisors LLC18,295$112.7K0.0%New
Essex Investment Management Co LLC18,221$112.2K0.0%−28
Mesirow Financial Investment Management, Inc.15,800$97.3K0.0%No change
Mercer Global Advisors Inc /adv12,775$78.7K0.0%New
Vanguard Global Advisers, LLC2,093$12.9K0.0%No change
Cambridge Investment Research Advisors, Inc.24,504$1500.0%+12,252
Acadian Asset Management LLC20,523$1250.0%−800
Barclays PLC13$800.0%New
Jpmorgan Chase & Co11$710.0%No change
Cassaday & Co Wealth Management LLC10$620.0%No change

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Champions Oncology is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARCHAMPIONS ONCOLOGY, INC.2
  • CIK0000771856
  • Employer ID (EIN)52-140175518
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company18
  • Incorporated inDelaware18
  • Fiscal year endsApril 302
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)2
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance2
  • Business address855 N. Wolfe Street, Suite 619, Baltimore, MD 212052
  • Phone410-369-03652
  • Shares outstanding13,918,569 as of Sep 9, 202616
  • Public float$28.6M as of Oct 31, 202518
  • AuditorEISNERAMPER LLP, Iselin, New Jersey PCAOB ID 274; no auditor attestation of internal control over financial reporting18
  • On EDGAR sinceSep 13, 19952
  • Filings653 in all: 4 (206), 8-K (156), 10-Q (55), 10QSB (39), 3 (30), 10-K (18), DEF 14A (16), UPLOAD (15)2
    All 45 form types

    10KSB (14), SC 13D/A (11), CORRESP (9), D (8), DEFA14A (8), SC 13D (8), 10-Q/A (6), 10KSB/A (3), 10QSB/A (3), 8-K/A (3), EFFECT (3), NT 10-K (3), SC 13G (3), SC 13G/A (3), 10-K/A (2), 4/A (2), 424B3 (2), CT ORDER (2), DEF 14C (2), DEFR14A (2), PRE 14C (2), PRER14C (2), S-1 (2), S-8 (2), 3/A (1), 424B4 (1), 5 (1), 8-A12B (1), CERTNAS (1), DEFC14A (1), DEFM14A (1), NT 10-Q (1), POS AM (1), PRE 14A (1), PRER14A (1), S-1/A (1), SCHEDULE 13G/A (1)

  • Latest filingsAnnual report (10-K) Jul 27, 2026
    Quarterly report (10-Q) Sep 11, 2026
    Proxy statement (DEF 14A) Aug 28, 2026
    Latest 8-K (8-K) Sep 10, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, par value $0.001 per shareCSBRNasdaq

From the cover page of the 10-K filed Jul 27, 2026 (Section 12(b) of the Exchange Act).18

Risk factors and legal proceedings

The risks Champions Oncology names in Item 1A of its 10-K filed Jul 27, 2026: 30 risks under these headings, as written.18

  • We historically incurred losses from operating activities, may require significant capital and may never achieve sustained profitability.
  • We may incur greater costs than anticipated, which could result in sustained losses.
  • We may not be able to implement our business strategies, which could impair our ability to continue operations.
  • Our laboratories are subject to regulation and licensure requirements, and the healthcare industry is highly regulated; we may face substantial penalties, and our business activities may be impacted, if we fail to comply.
  • If our laboratory facilities are damaged or destroyed, or we have a dispute with one of our landlords, our business would be negatively affected.
  • Any health crisis impacting our colony of laboratory mice could have a negative impact on our business.
  • We have limited experience marketing and selling our products and may need to rely on third parties to successfully market and sell our products and generate revenues.
  • We will continue to be dependent upon key employees.
  • Because our industry is very competitive and many of our competitors have substantially greater capital resources and more experience in research and development, we may not succeed in selling or increasing sales of our products and technologies.
  • If we are unable to protect our intellectual property, we may not be able to compete as effectively.
  • If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.
  • Claims by others that our products infringe their patents or other intellectual property rights could adversely affect our financial condition.
The other 18 risks
  • Research service studies are subject to cancellation based on changes in customer’s development plans.
  • We face competition in the life science market for computational software and for bioinformatics products.
  • Drug development programs, particularly those in early stages of development, may never be commercialized.
  • Impairment of goodwill may adversely impact future results of operations.
  • Our ability to use our net operating loss carry-forwards and certain other tax attributes may be limited.
  • We have a limited market for our common stock, which makes our securities very speculative.
  • Investment in our common stock may be diluted if we issue additional shares in the future.
  • Potential future sales or issuances of our common stock to raise capital, or the perception that such sales could occur, could cause dilution to our current stockholders and the price of our common stock to fall.
  • Our stock price is volatile and therefore investors may not be able to sell their common stock at or above the price they paid for it.
  • Certain provisions of our charter and bylaws and of our contractual agreements contain provisions that could delay and discourage takeover attempts and any attempts to replace our current management by stockholders.
  • Certain provisions of Delaware law make it more difficult for a third party to acquire us and make a takeover more difficult to complete, even if such a transaction were in the stockholders’ interest.
  • Our management and four significant stockholders collectively own a substantial majority of our common stock.
  • We have not paid any cash dividends in the past and have no plans to issue cash dividends in the future, which could cause the value of our common stock to have a lower value than other similar companies which do pay cash dividends.
  • If securities or industry analysts do not publish or cease publishing research or reports about us, our business or our market, or if they change their recommendations regarding our common stock adversely, the price of our common stock and trading volume could decline.
  • Our business operations could be disrupted if our information technology systems fail to perform adequately.
  • A pandemic, epidemic, or outbreak of an infectious disease in the United States or elsewhere may adversely affect our business and we are unable to predict the potential impact.
  • Deterioration in general economic conditions in the United States and globally, including the effect of prolonged periods of inflation on our customers and suppliers, could harm our business and results of operations.
  • Our Chairman of the Board of Directors resides in Israel and we have several customers with their operations located in Israel, and, therefore, our leadership continuity and results may be adversely affected by political, economic, and military instability in Israel.

Legal proceedings

To the knowledge of our management team, there is no litigation currently pending or contemplated against us, any of our officers or directors in their capacity as such, or against any of our property.

The opening of Item 3, Legal Proceedings.18

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52